IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
33.85
-0.72 (-2.08%)
At close: Jan 2, 2026, 4:00 PM EST
33.66
-0.19 (-0.56%)
After-hours: Jan 2, 2026, 7:44 PM EST
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$1,639,954
Profits / Employee
-$1,227,000
Market Cap
2.97B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131 | 7 | 5.65% |
| Dec 31, 2023 | 124 | 21 | 20.39% |
| Dec 31, 2022 | 103 | 22 | 27.16% |
| Dec 31, 2021 | 81 | 19 | 30.65% |
| Dec 31, 2020 | 62 | 15 | 31.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IDYA News
- 22 days ago - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 23 days ago - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers - PRNewsWire
- 4 weeks ago - IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away - Seeking Alpha
- 5 weeks ago - IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events - PRNewsWire